ImmunOs Therapeutics lures Novartis exec to its leadership team

Swiss biotech ImmunOs Therapeutics today announced the appointment of Dr Constanze Guenther as senior vice president, CMC and technical development.

Dr Guenther joins ImmunOs from Novartis (NOVN: VX), where she most recently served as global portfolio head, cell therapy, focusing on the successful transition of cell therapy programs from research to commercialization. In this role, she headed a team of technical project leads responsible for all CMC aspects of these programs. Previously at Novartis, Dr Guenther led a team of more than 300 associates as site head of the main European site for manufacturing of Kymriah, the first FDA approved cell therapy.

Prior to joining Novartis, she was Laboratory head of process development and analytics at Cytos Biotechnology, where she led a team of scientists and engineers responsible for process development and production of clinical material for various product candidates.